- Home
- CANG vs IMNM Comparison
CANG vs IMNM Comparison
Compare CANG & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- IMNM
- Stock Information
- Founded
- CANG 2010
- IMNM 2006
- Country
- CANG China
- IMNM United States
- Employees
- CANG N/A
- IMNM N/A
- Industry
- CANG Computer Software: Prepackaged Software
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- CANG Technology
- IMNM Health Care
- Exchange
- CANG Nasdaq
- IMNM Nasdaq
- Market Cap
- CANG 525.0M
- IMNM 585.5M
- IPO Year
- CANG 2018
- IMNM 2020
- Fundamental
- Price
- CANG $4.60
- IMNM $10.17
- Analyst Decision
- CANG
- IMNM Strong Buy
- Analyst Count
- CANG 0
- IMNM 5
- Target Price
- CANG N/A
- IMNM $28.60
- AVG Volume (30 Days)
- CANG 1.2M
- IMNM 881.8K
- Earning Date
- CANG 03-10-2025
- IMNM 11-13-2024
- Dividend Yield
- CANG N/A
- IMNM N/A
- EPS Growth
- CANG N/A
- IMNM N/A
- EPS
- CANG 0.19
- IMNM N/A
- Revenue
- CANG $38,020,222.00
- IMNM $10,129,000.00
- Revenue This Year
- CANG $253.48
- IMNM N/A
- Revenue Next Year
- CANG N/A
- IMNM N/A
- P/E Ratio
- CANG $24.32
- IMNM N/A
- Revenue Growth
- CANG N/A
- IMNM N/A
- 52 Week Low
- CANG $1.09
- IMNM $8.97
- 52 Week High
- CANG $9.66
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- CANG 48.91
- IMNM 42.41
- Support Level
- CANG $4.31
- IMNM $9.24
- Resistance Level
- CANG $4.72
- IMNM $11.06
- Average True Range (ATR)
- CANG 0.41
- IMNM 0.73
- MACD
- CANG -0.10
- IMNM -0.03
- Stochastic Oscillator
- CANG 28.26
- IMNM 39.41
About CANG Cango Inc. each representing two (2)
Cango Inc is an automotive transaction service platform in China connecting dealers, financial institutions, car buyers, and other industry participants. The services mainly consist of - automotive financing facilitation, automotive transaction facilitation, and aftermarket service facilitation. Geographically, it derives revenue from China.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.